Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17037252 | 0.79 | — | — | |
| SCHEMBL24983126 | 0.79 | — | — | |
| SCHEMBL8279389 | 0.75 | — | — | |
| SCHEMBL8278544 | 0.70 | — | — | |
| SCHEMBL21547466 | 0.69 | NPSR1 (0.33) | L3MBTL1 | |
| SCHEMBL8280351 | 0.69 | — | — | |
| SCHEMBL12797551 | 0.69 | POLB (0.31) | — | |
| SCHEMBL8279386 | 0.67 | MME (0.30) | — | |
| SCHEMBL10076626 | 0.67 | L3MBTL1 (0.35) | L3MBTL1 | |
| SCHEMBL8280288 | 0.67 | ACE (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828396-B2 | Alkyne compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9796741-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170298085-A1 | CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170298084-A1 | AMIDE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170260219-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-9758537-B2 | Compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS (US) | 2017-09-12 | — | — | US | disclosed |
| US-9732104-B2 | Ether compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732103-B2 | Carbamate, ester, and ketone compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9663543-B2 | Phosphonate compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9598446-B2 | Amino compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160362433-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160362432-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160361329-A1 | COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20150239921-A1 | Phosphonate Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239868-A1 | Alkyne Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239919-A1 | Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239895-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239838-A1 | Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239920-A1 | Ether Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362433-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, C9, TFPI | GAA 3630/4885L3MBTL1 2183/4885 |
| US-20150239868-A1 | Alkyne Compounds for Treatment of Complement Mediated Disorders | CFD, C9, TFPI | GAA 4083/4885L3MBTL1 1387/4885 |
| US-20150239838-A1 | Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, CFH | GAA 3292/4885L3MBTL1 2887/4885 |
| US-20160362432-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, CFH, TFPI | GAA 2902/4885L3MBTL1 3351/4885 |
| US-20170298084-A1 | AMIDE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, C9 | GAA 4379/4885L3MBTL1 1315/4885 |
| US-20160361329-A1 | COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, CFH, TFPI | GAA 2101/4885L3MBTL1 4004/4885 |
| US-20170260219-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, C1QBP | GAA 4206/4885L3MBTL1 1894/4885 |
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C9 | GAA 4693/4885L3MBTL1 1087/4885 |
| US-20150239920-A1 | Ether Compounds for Treatment of Complement Mediated Disorders | TFPI, CFD, C9 | GAA 4289/4885L3MBTL1 942/4885 |
| US-20150239895-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Complement Mediated Disorders | TFPI, CFD, F3 | GAA 4022/4885L3MBTL1 1951/4885 |
| US-20170298085-A1 | CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, C9, CFH | GAA 3663/4885L3MBTL1 1693/4885 |
| US-20150239921-A1 | Phosphonate Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C1QBP | GAA 4206/4885L3MBTL1 1894/4885 |
| US-20150239919-A1 | Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders | CFD, C9, CFH | GAA 3663/4885L3MBTL1 1693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.